Prof. Ronit Satchi-Fainaro, who led the team that developed the 3D-bioprinted...
Prof. Ronit Satchi-Fainaro, who led the team that developed the 3D-bioprinted glioblastoma model

Image source: Tel Aviv University

Brain cancer research

Researchers 3D-print entire active tumor

Researchers at Tel Aviv University (TAU) have 3D-printed a first-of-its-kind glioblastoma tumor that mimics a living cancer malignancy, powering new methods to improve treatment and accelerate the development of new drugs for the most lethal type of brain cancer.

Glioblastoma is notoriously fatal as it accounts for the majority of brain tumors and is highly aggressive. The average survival time of patients with glioblastoma is 14-15 months from diagnosis. Glioblastoma spreads quickly and in an unpredictable manner, making it particularly challenging to treat with existing approaches including surgery, radiation therapy, chemotherapy and certain targeted therapies. New drugs could drive better patient outcomes. However, existing drug development methods in the lab are time-consuming and don’t show how a treatment will work in an individual patient’s body. To address the matter, the TAU research team created the world's first fully functioning 3D model of a glioblastoma tumor, which includes 3D-bioprinted cancer tissue and the surrounding tumor environment that affects its development. The findings were published recently in the journal Science Advances.

Photo
Confocal microscopy image of the 3D-printed penta-culture vascularized glioblastoma model

Image source: Neufeld et al., Science Advances 2021 (CC BY-NC 4.0)

“Our innovation gives us unprecedented access to 3D tumors that better imitate the clinical scenario, enabling optimal investigation," says the study's lead researcher, Prof. Ronit Satchi-Fainaro of the Sackler Faculty of Medicine, the Sagol School of Neuroscience, and the Director of the Morris Kahn 3D-BioPrinting for Cancer Research Initiative at Tel Aviv University. “Cancer, like all tissues, behaves very differently in a petri dish or test tube than it does in the human body. Approximately 90% of all experimental drugs fail in clinical trials because the success achieved in the lab is not reproduced in patients. If we take a sample from a patient's tumor, together with surrounding tissues, we can 3D-bioprint from this sample 100 tiny tumors and test many different drugs in various combinations to discover the optimal treatment for this specific tumor,” she explains. “Alternately, we can test numerous compounds on a 3D-bioprinted tumor and decide which is most promising for further development and investment as a potential drug.”

Satchi-Fainaro adds that perhaps the most exciting aspect of her team’s breakthrough is identifying proteins and genes in cancer cells that can serve as new targets for drugs – a particularly difficult task when dealing with a tumor inside the brain of a living being. For example, the researchers were able to use their new technology to target a specific protein mechanism they had previously identified that causes the immune system to help glioblastoma spread, rather than attack deadly cancer cells. The experiment succeeded in delaying the growth and blocking the invasion of glioblastoma. According to Prof. Satchi-Fainaro, this innovative approach will not only enable the discovery of new drug targets, but also enable the development of new drugs at a much faster rate than today. She hopes that in the future, this technology will facilitate personalized medicine for patients.

We go to the operating suite, we extract tissue from the tumor and we print it according to the MRI of that patient. Then, we [...] can test all the different therapies to evaluate their efficacy for that specific tumor

Ronit Satchi-Fainaro

The 3D-bioprinted tumor is made from a gel composition that resembles the brain and includes a complex system of blood vessel-like tubes through which blood cells and drugs can flow, simulating how a real tumor develops and reacts to treatments. “The process in which we bio-print a tumor from a patient is that we go to the operating suite, we extract tissue from the tumor and we print it according to the MRI of that patient,” explains Satchi-Fainaro, who is also Director of the Cancer Biology Research Center and Head of the Cancer Research and Nanomedicine Laboratory at Tel Aviv University. “Then, we have about two weeks in which we can test all the different therapies to evaluate their efficacy for that specific tumor, and get back with an answer about which treatment is predicted to be the best fit.”

Using biological samples from patients, the researchers teamed up with Dr. Asaf Madi's lab at TAU's Department of Pathology, Sackler Faculty of Medicine, to conduct genetic sequencing of the cancer cells in the 3D model. With their approach, the researchers could replicate the specific growth rate and behavior of each tumor. As a result, Satchi-Fainaro says, "We proved that our 3D-printed model is better suited for predicting treatment efficacy, drug target discovery and new drug development.”

The 3D technology was developed by PhD student Lena Neufeld, together with other researchers at Satchi-Fainaro's laboratory: Eilam Yeini, Noa Reisman, Yael Shtilerman, Dr. Dikla Ben-Shushan, Sabina Pozzi, Dr. Galia Tiram, Dr. Anat Eldar-Boock and Dr. Shiran Farber. The 3D-bioprinted models are based on samples from patients, taken directly from operating rooms at the Neurosurgery Department of the TAU-affiliated Tel Aviv Sourasky Medical Center (Ichilov Hospital).


Source: Tel Aviv University

19.08.2021

Read all latest stories

Related articles

Photo

Brain tumour analysis

Glioblastoma '3D maps' help find new therapies

Researchers at the Universitat Autònoma de Barcelona obtained a highly accurate recreation of human glioblastoma’s features using a novel 3D microscopy analysis. The study, published in the…

Photo

‘Mini-Brains’: Evidence of Zika’s toll on fetal cortex

Studying a new type of pinhead-size, lab-grown brain made with technology first suggested by three high school students, Johns Hopkins researchers have confirmed a key way in which Zika virus causes…

Photo

Neurology

Supercomputer helps create 3D synthetic brain models

Scientists are using artificial intelligence (AI) and the Cambridge-1 supercomputer to synthesise artificial 3-D MRI images of human brains and create models that show disease states across various…

Related products

Agfa HealthCare – Drystar 5301

Printer

Agfa HealthCare – Drystar 5301

Agfa HealthCare
Agfa HealthCare – Drystar 5302

Printers

Agfa HealthCare – Drystar 5302

Agfa HealthCare
Agfa HealthCare – Drystar 5503

Printers

Agfa HealthCare – Drystar 5503

Agfa HealthCare
Agfa HealthCare – Drystar Axys

Printers

Agfa HealthCare – Drystar Axys

Agfa HealthCare
Canon – Artemis

Tomosynthesis

Canon – Artemis

Canon Medical Systems Europe B.V.
Cefla – NewTom Giano HR Range

Conebeam CT

Cefla – NewTom Giano HR Range

Cefla s.c.
Subscribe to Newsletter